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ABSTRACT
Over 150 mutations in the mitochondrial genome have
been shown to be associated with human disease.
Remarkably, two-thirds of them are found in tRNA
genes, which constitute only one-tenth of the mito-
chondrial genome. A total of 22 tRNAs punctuate
the genome and are produced together with 11
mRNAs and 2 rRNAs from long polycistronic primary
transcripts with almost no spacers. Pre-tRNAs thus
require precise endonucleolytic excision. Further-
more, the CCA triplet which forms the 30 end of all
tRNAs is not encoded, but must be synthesized by
the CCA-adding enzyme after 30 end cleavage. Amino
acid attachment to the CCA of mature tRNA is per-
formed by aminoacyl-tRNA synthetases, which, like
the preceding processing enzymes, are nuclear-
encoded and imported into mitochondria. Here, we
critically review the effectiveness and reliability of
evidence obtained from reactions with in vitro tran-
scripts that pathogenesis-associated mutant mito-
chondrial tRNAs can lead to deficiencies in tRNA
30 end metabolism (30 end cleavage, CCA addition
and aminoacylation) toward an understanding of
molecular mechanisms underlying human tRNA dis-
orders. These defects probably contribute, individu-
ally and cumulatively, to the progression of human
mitochondrial diseases.
INTRODUCTION
The human mitochondrial genome encodes 13 out of more
than 80 polypeptide subunits of the mitochondrial respiratory
chain complexes and contains 24 additional genes required for
mitochondrial protein biosynthesis (1,2). These include
2 rRNA genes and 22 tRNA genes, one for each of 18 amino
acids, and 2 each for tRNALeu (which read UUR and CUN
codons) and tRNASer (which read UCN and AGY codons).
The mitochondrial genome undergoes a 10- to 17-fold higher
rate of mutation than the nuclear genome (3). Most mitochon-
drial mutations lead to polymorphisms (considered to be
harmless), while a growing number correlate with various
disorders. Since 1988 when the first pathogenesis-associated
mutations in the mitochondrial genome were characterized
(4,5), over 150 disease-correlated mutations have been
found, about 100 of them located in tRNA genes [for a com-
pilation, see MITOMAP: A Human Mitochondrial Genome
Database 2004 (http://www.mitomap.org)]. The tRNA genes
make up only10% of the mitochondrial genome (Figure 1A);
these genes are thus ‘hot-spots’ for mutation-based mitochon-
drial pathogenesis.
The tRNA-linked disorders cover a wide range of symptoms
and syndromes, including myopathies, encephalopathies, car-
diopathies, deafness, ophthalmoplegia, diabetes and others.
The relationship between mutations and disorders is complex;
a single mutation can lead to different symptoms and different
mutations to the same disorder. All these mitochondrial tRNA
disorders more or less severely affect the energy metabolism
of the cell. Efforts to understand the molecular mechanisms
underlying their genotype/phenotype relationships have been
made over the last 15 years; numerous reviews summarize the
clinical and biological aspects (6–13) or the molecular
mechanisms affected during the tRNA life cycles (14–18).
Owing to their central function in protein synthesis, the mal-
function of mutant tRNAs is thought to play a key role in the
corresponding mitochondrial pathologies and has therefore
been extensively investigated. Various aspects were explored,
emphasizing aminoacylation properties and steady-state levels
of aminoacyl-tRNA in mitochondria, but also including tRNA
synthesis, structure, stability and interaction with partners of
the translational machinery. However, so far only a limited
number of mutations and of tRNAs have been explored, and
for each, only one or a subset of possibilities were investigated.
Neither general rules nor common features have emerged, and
further studies are thus necessary.
Studies are complicated due to intrinsic properties of mito-
chondria and mitochondrial tRNAs (heteroplasmy, limited
access to natural material and almost no possibility for genetic
manipulation). Mitochondria are present in hundreds of copies
per cell, each of them carrying more than one copy of DNA. A
mitochondrial mutation can thus be heteroplasmic, varying in
proportion to wild-type from 0 to 100% mutated DNA in the
different tissues of an affected patient (Figure 1B). The thresh-
old for effect of a mitochondrial mutation is usually between
15 and 50% of the normal functional level (referring to a
combination of the proportion of the mutant tRNA in the
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heteroplasmic population with the effect of the mutation on
processing, aminoacylation and function in translation;
Figure 1C). Above the upper threshold, no pathology is
observed, and below the lower threshold, the condition would
be lethal. The heteroplasmic state also complicates analysis and
interpretation of mutational effects. To minimize this problem,
cybrid cells homoplasmic for a specific mutation can be pro-
duced by fusion of enucleated patient cells with a r0 cell line
lacking mitochondria (19). Although such cells allowed the
evaluation of several properties of mutated tRNAs (e.g.
steady-state level of aminoacylation, stability and post-
transcriptional modification), their construction is difficult
and time consuming, so that only a handful of mutations have
been analyzed so far. Moreover, the variety of cell types used to
generate cybrids with different nuclear backgrounds (e.g. HeLa,
osteosarcoma and lymphoblasts) doesnot allow straightforward
comparisons (14). Ex vivo analyses, based on purification of a
specific tRNA from cultured cells or from biopsies, are very
powerful but have quantitative limitations (20,21).
The alternative approach, which avoids heteroplasmic
effects in the study of pathological tRNAs and gives access
to a sufficient amount of material, uses enzymes that are either
recombinantly expressed or extracted from cultured cells with-
out mitochondrial diseases, and tRNA substrates or precursors
that are produced by in vitro transcription. This approach has
recently made it possible to investigate the effects of several
point mutations on various aspects of tRNA metabolism
(Figure 2). Here, we review the defects in mitochondrial
tRNA 30 end metabolism revealed by in vitro studies, including
processing (cleavage of the 30-trailer and CCA addition) and
Figure 1. (A) Human mitochondrial gene map. H with counterclockwise arrow and L with clockwise arrow designate direction of heavy and light DNA strand
transcription. Outer ring is the light transcript, and inner ring is the heavy transcript. rRNAs and mRNAs are filled in with colors. Black bars designate tRNAs which
punctuate the mitochondrial genome. (B) Heteroplasmy. Mixed (heteroplasmic) populations of wild-type and mutant mitochondrial genomes are present. Filled
circles indicate mutant mitochondrial genomes and open circles indicate wild-type. (C) Thresholds. The thresholds for pathology are typically between 15 and 50% of
mitochondrial tRNA function, affected by the extent of heteroplasmy (B) combined with effectiveness of the mutant tRNA in the series of reactions illustrated
(Figure 2), in translation, and with its stability. A lower functional level would be lethal and a higher level would be without a phenotype.
Figure 2. The tRNA end processing pathway followed by aminoacylation. (A) tRNA is transcribed as a precursor, with a 50 end leader and a 30 end trailer. (B) RNase P
has endonucleolytically cleaved the tRNA at +1. (C) tRNAse Z endonucleolytically cleaves the precursor on the 30 side of the discriminator base (N; +73). (D) CCA-
adding enzyme (CCAse) adds CCA to the 30 end of the tRNA (N) produced by tRNase Z cleavage. (E) tRNA is charged with the cognate amino acid by a specific
aminoacyl-tRNA synthetase (aaRS). Dashed line from CCA in (D) to tRNAse Z between (B) and (C) with an X through it indicates that 30-CCA of mature tRNA is a
tRNase Z anti-determinant (39).
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aminoacylation. Point mutations in mitochondrial tRNAs may
contribute to tRNA malfunction by affecting the efficiency of
one or a combination of these reactions. Advantages and limita-
tions of the in vitro approach within the framework of investi-
gating molecular mechanisms of human mitochondrial tRNA
disorders will be discussed below.
tRNA 30 END METABOLISM
The 22 human mitochondrial tRNAs are synthesized from
polycistronic precursor transcripts where they are interspersed
among 11 mRNAs and two rRNAs (2,22,23), often with no
spacers (Figure 1A). Table 1 provides details on the neighbor-
hood of each tRNA gene. In about half the cases, tRNA exci-
sion from primary transcripts leads to mature mRNAs and
rRNAs with proper ends, others are either flanked by a
small (1–2 nt) spacer and several even overlap by one residue
with the adjacent RNA, as in the case of tRNATyr/tRNACys.
Therefore, the processing of mitochondrial tRNAs requires
precise endonucleolytic cleavage at both 50 and 30 ends
(Figure 2). Pre-tRNA 30 ends are subsequently completed by
the addition of the CCA triplet, and a subset of nucleotides
becomes post-transcriptionally modified. Finally, mature and
correctly folded tRNAs are esterified at the 30 end with the
cognate amino acid by the corresponding aminoacyl-tRNA
synthetase. They are subsequently carried to the ribosome by
translation factor [elongation factor (EF)-Tu], allowing protein
synthesis. This brief overview illustrates the importance of 30
end metabolism for both tRNA synthesis and tRNA function.
Mutations in tRNAs may affect the reaction efficiency of the
enzymes involved in tRNA 30 end metabolism in a direct way,
or indirectly via changes in structural properties of the pre-
cursor or mature tRNA. Importantly, in this context, human
mitochondrial tRNAs deviate structurally from classical
tRNAs (24). Most extreme is tRNASer(AGY), in which the
entire D-domain is missing, and an extended anticodon
stem is present. Other tRNAs possess all expected secondary
structural domains and can be folded into a cloverleaf. Large
variations in the size of the D-loop, and especially T-loop
(which is strictly maintained at 7 nt in canonical, nuclear-
encoded tRNAs), are observed, and classically conserved or
semi-conserved nucleotides (e.g. GG in the D-loop, UUC con-
verted into TCC in the T-loop), however, are absent. These
common deviations from canonical secondary structure lead,
in turn, to unpredictable tertiary interactions, suggesting
greater flexibility of mitochondrial tRNAs. Owing to the
nucleotide composition bias of the two mitochondrial DNA
strands (1), 14 tRNAs (transcribed from the heavy strand;
Figure 1A) are A-rich (36%) and G-poor (14%), and eight
tRNAs (transcribed from the light strand) are U-rich
(31.6%) and C-poor (16.4%), weakening the helical domains
of tRNA secondary structures (24). These structural peculia-
rities may influence all aspects of the life-cycle of human
mitochondrial tRNAs and contribute to the effects of patho-
genic mutations.
CLEAVAGE OF tRNA 30-TRAILERS
tRNA end processing
Excision of tRNAs from primary polycistronic mitochondrial
transcripts is catalyzed by two specialized enzymes, RNase P
and tRNase Z (the tRNA 30 end processing endonuclease,
previously known as 30-tRNase or RNase Z). Although not
obligatory, a reaction order favoring cleavage by RNase P at
the 50 end of a pre-tRNA followed by tRNase Z 30 end cleavage
Table 1. tRNA punctuation and 30 end sequence
tRNA Stranda NTb 50 Flanking genec 30 Flanking genec Note on flanking gene(s)d 30 End flanking sequencee
Phe H 577–674 — 12S rRNA Contiguous A/AAU
Val H 1602–1670 12S rRNA — Contiguous A/GCU
Leu(UUR) H 3230–3304 16S rRNA ND1 mRNA Contiguous/50 end at 3307 A/ACA
Ile H 4263–4331 ND1 mRNA — Needs 1 A A/GGA
Met H 4402–4469 — ND2 mRNA Contiguous A/AUU
Trp H 5512–5579 ND2 mRNA — Contiguous G/UAA
Asp H 7518–7585 — COX2 mRNA Contiguous A/AUG
Lys H 8295–8364 — ATP8 mRNA Contiguous A/AAU
Gly H 9991–10058 COX3 mRNA ND3 mRNA Both contiguous A/AUA
Arg H 10405–10469 ND3 mRNA ND4 mRNA Needs 2 As/Contiguous A/AUG
His H 12138–12204 ND4 mRNA tRNASer(AGY) Needs 1 A/Contiguous C/GAG
Ser(AGY) H 12207–12265 tRNAHis tRNALeu(CUN) Both contiguous A/ACU
Leu(CUN) H 12266–12336 tRNASer(AGY) ND5 mRNA Both contiguous A/AUA
Thr H 15888–15953 — — — A/AAU
Pro L 16203–15955 — — — U/UUG
Glu L 14742–14674 — — — A/AGU
Ser(UCN) L 7516–7446 — — — G/UCU
Tyr L 5891–5826 — tRNACys Contiguous A/GCU
Cys L 5826–5761 tRNATyr — Needs 1 A U/CUC
Asn L 5729–5657 — tRNAAla 50 end at 5655 G/UAA
Ala L 5655–5587 — — — A/GCU
Gln L 4400–4329 — — — G/AAA
aH or L designates DNA strand transcribed (see Figure 1).
bRefers to position in the mitochondrial genome (1).
cGene product encoded immediately upstream (50 flanking gene) or downstream (30 flanking gene) of the tRNA. In columns 4 and 5, ‘—’ indicates no gene product
encoded immediately upstream or downstream of the tRNA, respectively.
dStates whether the flanking gene on the 50 or 30 side of the tRNA is contiguous, requires addition of one or two As to the 30 end after tRNA excision or has a short spacer.
e30 End sequence presented as discriminator base/following 3 nt.
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(Figure 2A–C) is observed in many systems, including higher
plants (25), human mitochondria (26) and budding yeast (27).
While RNase P efficiently cleaves substrates with long 30 end
trailers, tRNase Z is apparently sensitive to the length of the
50-leader (28). Experiments discussed below have therefore
been performed on simplified model substrates.
Characterization of tRNase Z
Interestingly, the single fruit fly tRNase Z gene encodes both
the nuclear and mitochondrial enzymes (29), and the ratio of
nuclear/mitochondrial distribution in such cases is often20:1
(A. Hopper, personal communication). tRNase Z RNAi knock-
downs cause the accumulation of both nuclear-encoded and
mitochondrial pre-tRNAs with 30 end extensions, but did not
produce a phenotype or reduce the amount of mature cyto-
plasmic tRNA. The amount of mature mitochondrial tRNAIle
and tRNATyr, however, was clearly reduced (29). The con-
centration of tRNase Z is thus more likely to be limiting in
mitochondria than in nuclei, but issues of steady-state con-
centration and half-life of both the processing enzyme and the
tRNA product must also be considered.
Human tRNase Z has also been cloned, recombinantly
expressed and partially characterized, leading to the conclu-
sion that these enzymes belong to the ELAC family (30). Both
human homologs ELAC1 and ELAC2 (the short and long
forms, respectively) possess the tRNase Z activity (31). It is
unclear why humans and a number of other metazoans encode
multiple forms of tRNase Z. Sorting servers (e.g. Mitoprot;
http://ihg.gsf.de/ihg/mitoprot.html) predict that only the long
form (ELAC2) carries an N-terminal mitochondrial targeting
sequence, and ELAC2 has a lower KM and a wider substrate
range than ELAC1 (32), consistent with ELAC2 function as
mitochondrial tRNase Z. Since the human mitochondrial form
of tRNase Z has not yet been proven, however, tRNase Z
activity was obtained from HeLa mitoplast extracts for the
analysis of mitochondrial tRNA 30 end processing (26,33,34).
ELAC2 was first characterized as a prostate cancer suscept-
ibility gene (35). Two of the identified mutations which are
weakly linked to prostate cancer are located in or close to the
phosphodiesterase II domain, the active site of tRNase Z.
ELAC2 is associated with mitotic spindles (36), and the
RNAi knockdown of the Caenorhabditis elegans homolog
of ELAC2 interferes with germline proliferation (37), but a
possible function in mitochondrial tRNA processing, in which
certain mutations increase the risk of human prostate cancer, is
also worth considering.
CCA, a tRNase Z anti-determinant
The CCA triplet needed at the 30 end of all mature tRNAs is not
mitochondrially encoded (rightmost column in Table 1), and
must thus be added to the discriminator base (the last encoded
30 end nucleotide) by CCA-adding enzyme after 30 end pro-
cessing. Mature in vitro transcribed tRNA with CCA at its
30 end is a tRNase Z anti-determinant (38,39); dashed line with
an X through it; Figure 2D!B,C; [for an alternative inter-
pretation see (40)], being neither a substrate for nor an
inhibitor of tRNase Z. This ensures that mature tRNA proceeds
smoothly to aminoacylation without recycling through tRNase
Z. Interestingly, a partial CCA terminus consisting of –CC is
sufficient to produce the anti-determinant effect.
The CCA terminus is also a tRNase Z anti-determinant in
Bacillus subtilis, in which the CCA triplet is encoded in some
tRNA genes, while it must be added post-transcriptionally to the
transcriptsofothers.KnockoutofB.subtilis tRNaseZshowsthat
most of the CCA-containing pre-tRNAs are processed by a
30-exonuclease, while those without encoded CCA are pro-
cessed endonucleolytically (41). In Thermotoga maritima,
CCA is transcriptionally encoded at the 30 end of tRNA genes.
Surprisingly, CCA is a cleavage site determinant in this
organism, guiding tRNase Z to efficiently cleave downstream
of the CCA triplet instead of after the discriminator base (42).
Defective tRNA end processing as a model for
pathogenesis in vivo
The evidence which led to a model linking defective tRNA
processing to pathogenesis was first obtained from studies of
mitochondrial RNA in cells harboring disease-associated
mutations in tRNALeu(UUR) (43,44). This tRNA gene is located
between the genes for 16S rRNA and the ND1 subunit
(Figure 1A). There is no spacer between the 30 end of 16S
rRNA and position +1 of tRNALeu(UUR), and only a 2 nt spacer
is present between the discriminator base of tRNALeu(UUR) and
the initiation codon of the ND1 message (Table 1). An increase
in the steady-state concentration of a discrete precursor (RNA
19) consisting of the linked 16S rRNA-tRNALeu(UUR)-ND1
RNA was observed with the A3243G and A3302G mutations
(43,44), which are located in the D-loop and acceptor stem of
the gene product, respectively (see Figure 3).
Reduced tRNase Z processing efficiency of
pathogenesis-associated tRNA precursors
The hypothesis that pathogenesis-associated mutations could
cause defective tRNA end processing, thereby contributing to
disease, was further investigated in vitro using precursors with
both 50 and 30 end extensions (26,33,45). We have tested the
hypothesis that pathogenesis-associated mutations in tRNAs
could reduce the efficiency of precursor 30 end cleavage
using wild-type and pathogenesis-associated mutations in
tRNASer(UCN) (26), tRNAIle (46) and tRNALeu(UUR) (34)
(Figure 3 and Table 2). According to this hypothesis, poor
excision of tRNA could contribute to pathology. This would
only be the case, however, if the intra-mitochondrial concen-
tration of the processing enzyme is limiting.
The clearest example of a pathogenesis-associated mutation
which could cause defective tRNA 30 end processing is the
T7445C substitution in tRNASer(UCN), which causes
non-syndromic deafness (47,48). T7445C falls just on the
30-side of the discriminator base of tRNASer(UCN) (Figure 3),
outside of the mature tRNA, suggesting that processing reac-
tions depending on tRNA structure or sequence would be
unaffected. The mutation, however, changes 30 end processing,
leading to defective 30 ends (47). The cell lines homoplasmic
for T7445C display approximately one-third of the steady-
state level of tRNASer(UCN) observed in homoplasmic
wild-type sibling cell lines (48). Interestingly, the T7445C
substitution changes the sequence following the discriminator
base (underlined) from G/UCU– to G/CCU–, a tRNase Z anti-
determinant [discussed above and in (39)]. The pathogenesis-
associated T7445C tRNA precursor could not be cleaved
in vitro, while wild-type tRNASer(UCN) could be processed
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efficiently (26). Additionally, tRNASer(UCN) with an extra G at
the boundary between the V-loop and the T-stem (7472insG)
seems to be processed and aminoacylated less efficiently than
the normal tRNA (49,50). A possible rescue function for 30-
exonucleases in mitochondria [e.g. in cells with the T7445C
mutation in tRNASer(UCN)] has been discussed previously
(26,50). In principle, any endonucleolytic cleavage which
unlinks tRNASer(UCN) from the neighboring tRNATyr located
2.5 kb downstream (Figure 1A) could be followed by 30-
exonucleolytic cleavage to the discriminator.
Among trinucleotides found at the 30 end of human mito-
chondrial tRNAs following the discriminator base, /CCA is
not observed, nor is /CC, and /C is found only once (in
tRNACys; rightmost column in Table 1). In six cases [tRNAMet,
Figure 3. Mitochondrial tRNAs and pathogenesis-associated mutations analyzed for their effects on 30 end processing, CCA addition and/or aminoacylation.
(A) tRNASer(UCN), (B) tRNAGly, (C) tRNAIle, (D) tRNALeu(UUR) and (E) tRNALys. tRNAs are represented in their secondary cloverleaf structures. Mutations detected
so far in the corresponding genes are indicated by arrows, and numbering is according to the mitochondrial genome (1). Black arrows and numbers refer to pathology-
related mutations for which one or more of the enzymatic activities described here have been studied (see Table 2); grey numbers and arrows identify those
pathology-related mutations which have not yet been characterized as to their effects on any of these reactions (MITOMAP).
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tRNAAsp, tRNALys, tRNAGly, tRNAArg and tRNALeu(CUN)],
the trinucleotide following the discriminator base is a
mitochondrial translation initiation codon (/AUG, /AUA,
/AUU or /AAU). Genes for tRNAPhe and tRNAThr, like
tRNALys, also have the trinucleotide AAU following the dis-
criminator base, although the sequence immediately down-
stream does not encode a polypeptide in these cases. In
conclusion, there is no natural tRNase Z anti-determinant in
the sequences of 21 tRNA genes, and /C in tRNACys would not
be expected to have much effect.
The kinetics of tRNase Z processing was performed using
eight substitutions in tRNAIle associated with cardiomyopathy
or ophthalmoplegia (46), and three in tRNALeu(UUR) correlated
with mitochondrial encephalomyopathy with lactic acidosis
and stroke-like episodes (MELAS) and assorted myopathies
(34) (Figure 3). Four of the mutations (A4269G, A4295G,
G4309A and A4317G) reduce the tRNase Z reaction efficiency
up to 10-fold, and three tRNALeu(UUR) mutations decrease
the efficiency up to 3-fold relative to wild type (Table 2),
all due to lower Vmax. Interestingly, in tRNA
Leu(UUR), the
reduction in processing efficiency increases with proximity
to the 30 cleavage site (WT > A3243G > A3302G 
C3303U). These results support the hypothesis that 30 end
processing defects are among the molecular events involving
mutant mitochondrial tRNAs which contribute to mitochon-
drial tRNA disorders. Note, however, that there can be dis-
crepancies between results obtained with wild-type and mutant
tRNAs from cybrid cells and those from in vitro transcripts
when it is possible to directly compare them. For example, the
tRNAIle mutation A4269G was demonstrated to affect stability
without any evident effect on maturation when the tRNAs
were extracted from homoplasmic cybrid cells (51).
RNase P
This review is principally concerned with reactions at the
30 end of tRNA and mitochondrial pathogenesis, but for the
sake of completeness, 50 end cleavage by RNase P should
also be mentioned. Human mitochondrial RNase P activity
was found by some to be indistinguishable from nuclear
RNase P (52,53), while others found rat and human mito-
chondrial and nuclear RNase P to have different character-
istics (33,54). The composition of human mitochondrial
RNase P has not been completely resolved because it is
difficult to purify mitochondria free of cytosolic or nuclear
contamination (55). The number of RNase P molecules per
mitochondrion required to process the mitochondrial tran-
scripts could be very low (53), and if the intra-mitochon-
drial concentration of enzymes involved in tRNA
metabolism is limiting, the modest reductions in processing
efficiency arising from mutations in tRNA could lead to the
accumulation of precursors and reduce the amount of func-
tional mature tRNA.
SYNTHESIS OF THE CCA TERMINUS
Cloning, expression and characterization of tRNA
nucleotidyltransferase
tRNA requires the base triplet CCA at the 30-terminus for its
aminoacylation and participation in protein synthesis. In
mitochondrial tRNAs, this sequence must be added post-
transcriptionally as an essential step in tRNA maturation
(Figure 2). CCA addition is catalyzed by CCA-adding
enzymes which are conserved in all organisms of all king-
doms. In humans, the mitochondrial, nuclear and cytosolic
forms of this enzyme are encoded by a single gene located
on chromosome 3 (56). A mitochondrial target sequence
encoded in exon 1 ensures delivery of a proportion of the
CCA-adding enzyme to mitochondria. Importantly, both the
tRNase Z and CCA-adding enzyme are encoded in both forms
by using two or three in-frame start codons separated by a
short distance, with the mitochondrial targeting sequence
being present only when translation initiates at the upstream
AUG. Since CCA-adding enzymes are closely related to
poly(A) polymerases, these enzymes were sometimes mista-
kenly identified by sequence analysis (57,58). The recombi-
nant enzymes, however, can easily be distinguished based on
their biochemical activity. The human CCA-adding enzyme
was therefore cloned, recombinantly expressed and character-
ized (56,59). While showing kinetic properties comparable to
those of other CCA-adding enzymes, the human enzyme has a
specific affinity for mitochondrial tRNAs which lack some of
the canonical elements, such as the TCC-loop. The N-terminal
domain of this enzyme contains the catalytic core as well as
features such as nucleotide recognition/discrimination and
specificity for tRNA (60,61). Recent domain swap experi-
ments between the CCA-adding enzyme and poly(A) poly-
merase indicate that C-terminal domains also contribute to the
discriminatory power of CCA addition (62).
Influence of pathology-related mutations on
CCA addition
The activity of CCA-adding enzyme can be influenced by
changes in sequence and/or structure of substrate tRNAs
which can consequently contribute to pathogenicity, as first
reported in certain disease-associated mutations in mitochon-
drial tRNAIle and tRNAGly (63) as well as tRNALeu(UUR) (34).
In both tRNAIle and tRNAGly, an A was replaced by G in the
TCC-loop (A4317G in tRNAIle and A10044G in tRNAGly;
Figure 3). These two domains combine to form the ‘elbow’ of
the L-shaped three-dimensional (3D) structure of tRNA, a
recognition element for CCA-adding enzymes (64–67). Struc-
ture probing experiments on in vitro transcripts carrying these
replacements revealed that they lead to an aberrantly stable
TCC-arm or to a weakened interaction between the TCC- and
D-loop, respectively (63). In the kinetic analysis, KM values
were only slightly affected, indicating that the enzyme’s affi-
nity for the mutated tRNAs was not reduced. The observed
decrease in kcat suggests that the chemical step of catalysis is
affected, possibly due to an inappropriate orientation of the
tRNA substrate in the catalytic core of the enzyme (63).
Besides tRNAIle and tRNAGly, five pathogenic mutations in
tRNALeu(UUR) were investigated for their effects on CCA addi-
tion (Figure 3) (34). Only the substitution closest to the
30-terminus, C3303T (causing cardiomyopathy), showed a
significant effect on CCA addition (Table 2), reducing
nucleotide incorporation by a factor of 5.5. While Vmax was
unaffected, KM increased, indicating that C3303T reduces the
affinity of the CCA-adding enzyme for tRNA without inter-
fering with catalysis.
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These examples show that pathogenesis-associated muta-
tions which affect the same enzymatic reaction can do so by
different means, either interfering with catalysis (as in
A4317G in tRNAIle and A10044G in tRNAGly) or affecting
the strength of enzyme–substrate interaction [C3303T in
tRNALeu(UUR)]. Furthermore, the same mutation [C3303T
in tRNALeu(UUR)] affects two different enzymes differently,
causing a decrease in the Vmax of tRNase Z and an increase in
the KM of CCA-adding enzyme (34).
AMINOACYLATION
Once the tRNA is synthesized (i.e. the steps of 50 and 30 end
cleavage and CCA addition are finished as in Figure 2A!D,
post-transcriptional modifications are complete and 3D fold-
ing has taken place), the amino acid can be attached by the
cognate aminoacyl-tRNA synthetase (aaRS; Figure 2D!E). It
can then be brought to the ribosome by transient binding to
translation factors, allowing transfer of the amino acid to the
growing polypeptide chain, thereby fulfilling its fundamental
role in protein synthesis.
Mitochondrial aminoacyl-tRNA synthetases
Eukaryotic cells contain at least two sets of aminoacyl-
tRNA synthetases, one devoted to cytoplasmic protein synth-
esis, the other to translation of the mitochondrial genetic
information. In humans, cytosolic and mitochondrial enzymes
are generally encoded by distinct genes, with the exception of
GlyRS and LysRS [(68); C. Florentz, unpublished]. Enzymes
targeted to mitochondria are synthesized with a mitochondrial
signal sequence which is cleaved after import. Interestingly,
mitochondrial synthetases recognize not only mitochondrial
but also cytosolic tRNAs and tRNAs from other organisms; on
the other hand, mitochondrial tRNAs are not recognized by
non-cognate enzymes (69), probably due to their unusual
structural properties.
Specific recognition of a tRNA by its cognate aaRS is based
on the presence of ‘identity elements’, usually a set of bases or
base pairs in the tRNA. Such elements have been defined
precisely for a large number of bacterial, archaeal and
lower eukaryotic tRNAs (70,71) but remain largely unknown
for human mitochondrial tRNAs. Efficient aminoacylation
also depends on structural features within the tRNA and on
more global conformational properties.
Mutations in mitochondrial tRNAs reduce
aminoacylation efficiency
To evaluate the impact of the mutations in pathology-related
tRNAs on aminoacylation, wild-type and mutant mitochon-
drial tRNAs have been prepared by in vitro transcription and
aminoacylated by the corresponding recombinantly expressed
aminoacyl-tRNA synthetases. The first aminoacylations tested
in such an in vitro system were those specific for serine and
isoleucine. The serine system contributed to a funda-
mental understanding of tRNA/aaRS recognition, but
pathology-related mutations were not analyzed (72,73).
In contrast, 10 pathology-related mutations within tRNAIle
associated with either ophthalmoplegia or cardiomyopathy
were tested in the presence of a crude mitochondrial enzymatic
extract (74) or with cloned and over-expressed IleRS (75,76)
(Figure 3). Some mutations strongly reduce the ability of the
tRNA to be aminoacylated, while others have only a very
limited effect (Table 2). Mutations correlated with ophthal-
moplegia reduced the isoleucylation efficiencies (as measured
by the ratio kcat/KM compared to wild-type) from between 25-
and 50-fold to more than 1000-fold. More modest reductions
in aminoacylation efficiencies (or no effect) were reported for
mutations correlated with cardiomyopathies (75,76). Mutants
with compensatory mutations that restore disrupted base pair-
ing regain wild-type aminoacylability. The structural effects of
the mutations thus provide a stronger explanation for the
reductions in aminoacylation efficiency than direct interfer-
ence in tRNA/synthetase recognition. The analysis of tRNAIle
variants also revealed that a mutant tRNA can potentially
compete for the corresponding wild-type tRNA by inhibiting
its aminoacylation. This situation could mimic the in vivo case,
in which wild-type and mutant tRNAs co-exist in heteroplas-
mic patient cells (Figure 1B).
The use of in vitro transcripts leads to difficulties for inves-
tigation of aminoacylation properties of several human mito-
chondrial tRNAs other than tRNAIle and tRNASer because
the corresponding wild-type transcripts do not fold into the
expected cloverleaf secondary structures. The cases of
tRNALys and tRNALeu(UUR) are of particular interest.
Wild-type tRNALys folds into an extended hairpin (77)
due to the absence of a particular post-transcriptional mod-
ification, the N1-methyl group on adenine 9 (78). This methyl
group prevents base pairing of nucleotides 9 [position 8303 in
the mitochondrial genome, (see Figure 3)] and 64 (position
8355) from producing an extended acceptor stem in native
tRNALys. The role of this methyl group has been mimicked in
an in vitro transcript by mutating either nucleotide 9 or 64 to
prevent them from base pairing (77). The corresponding
‘pseudo-wild-type’ transcripts fold into the cloverleaf struc-
ture and become active in aminoacylation with kinetic prop-
erties close to those of cytoplasmic human tRNALys (79). By
second-site mutation of such ‘pseudo-wild-type’ transcripts,
it became possible to investigate the effect on aminoacylation
of all pathology-related mutations described so far in the
mitochondrial tRNALys gene (79). Two (G8313A and
G8328A) out of the eleven pathology-related mutations
lead to a very strong loss (5000- to 7000-fold) in aminoa-
cylation efficiency (kcat/KM); the other mutations had mild (2-
to 10-fold losses in efficiency) or no effects. Thus, as in the
case of tRNAIle, only a subset of mutations affects aminoa-
cylation. The mechanisms by which the G8313A and
G8328A mutations affect lysylation are unknown. Both
mutations are located in the anticodon branch (anticodon
domain and D-domain) on the same side on a model L-
shaped 3D tRNA structure where they could directly interfere
with LysRS interaction (79), while mutations without effect
are located on the opposite side or in the amino acid accept-
ing branch. Alternatively, these mutations could cause large
structural rearrangements of the tRNA, leading indirectly to
failure of synthetase recognition.
tRNALeu(UUR) has also been prepared by in vitro transcrip-
tion. The cloned and purified human mitochondrial LeuRS
accepts this transcript as a substrate at a 16- to 50-fold
lower efficiency than native tRNALeu(UUR) extracted from
cell lines (21,80). Here, the transcript only folds partially
into a tRNA structure, despite the presence of sequence ele-
ments typical of classical tRNAs required for correct folding.
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Indeed, the amino acid acceptor stem and the TCC-arm fold
normally, but a large ‘floppy’ domain is observed instead of
well-defined D and anticodon domains (34,80,81). Footprint-
ing experiments suggest that the synthetase induces a struc-
tural change within the tRNA, leading to a productive
interaction. Several mutations were analyzed to determine
their effects on leucylation (Figure 3 and Table 2). For exam-
ple, the effects of MELAS mutation A3243G and a second
mutation at the same position correlated with encephalomyo-
pathy (A3243T) lead to different effects (21,80). While muta-
tion A3243G displays 10-fold reduced efficiency of
aminoacylation, A3243T leads to a 300-fold decrease. The
T3271C substitution in the anticodon stem has only a 3-
fold negative effect, which can be reversed by a compensatory
mutation (82). As was found for tRNAIle and tRNALys, muta-
tions can affect aminoacylation efficiency either through kcat
or through KM. Local structural perturbations were observed
between some pathogenesis-associated mutations and wild-
type tRNALeu(UUR) (80,82).
The structurally unorganized domain in tRNALeu(UUR) pre-
pared by in vitro transcription, as opposed to the well-folded
native tRNA extracted from cell lines (83), can be stabilized so
as to more closely resemble a canonical structure. The site-
directed mutagenesis that replaces CA mismatches in either
the D-stem or the anticodon stem by G-C pairs leads to clo-
verleaf structures, thus improving aminoacylation efficiency
(81,83). These ‘pseudo-wild-types’ represent valuable refer-
ence molecules for a systematic investigation of pathology-
related mutations on tRNALeu(UUR) functions.
CHANGE IN 30 END METABOLISM OF
MITOCHONDRIAL tRNAs IS AN IMPORTANT
CONSEQUENCE OF MUTATION
Pathology-related mutations affect 30 end metabolism
Analysis of transcribed wild-type or engineered ‘pseudo-wild-
type’ substrates (tRNAs and tRNA precursors), or mutated
derivatives, allow the effects of mutations to be screened
in vitro. Mutations were found to affect any combination of
the activities involved with 30 end metabolism of tRNAs
(Figure 2B–E): cleavage of the 30-trailer, CCA addition and
aminoacylation. Although data summarized in Table 2 are not
yet complete, it is clear that for many mutations, at least one of
the three activities is significantly affected, making the 30 end
of tRNAs a reasonable place to look for the effect of patho-
genesis-associated mutations. Only three mutations have been
tested for their effect on all three functions. Among these,
mutation A3243G in tRNALeu(UUR) leads to a weak effect
on 30 end cleavage (2.2-fold decrease in efficiency), no effect
on CCA addition and a mild effect on aminoacylation (2- to
12-fold decrease in efficiency). The other two, A4317G in
tRNAIle and C3303T in tRNALeu(UUR), substantially reduce
the efficiency of 30 end cleavage and CCA addition but
have little or no effect on aminoacylation. Nine mutations
in tRNAIle have been tested for their effect on both 30 end
cleavage and aminoacylation. For some of them (4269, 4295
and 4320), cleavage of the 30 end trailer of the primary tRNA
transcript is reduced but aminoacylation is not affected; for
others (4274, 4284 and 4300), 30 end maturation is unaffected,
but reduced efficiency of aminoacylation is observed.
Whatever the affected activity, the end result is expected to
be the same, a decrease in aminoacyl-tRNA available for
protein synthesis. While the effect can differ at every level,
an accumulation of small effects on several aspects of tRNA
metabolism could lead to a strong global negative effect, suf-
ficient to place the level of mitochondrial protein synthesis
within the zone of pathology (Figure 1C). Indeed, limiting the
amount of aminoacyl-tRNA, by any means, reduces the rate of
translation (84,85). Such reductions have been observed in
vivo in many cases involving pathogenesis-associated mito-
chondrial tRNAs (49,86–89). For some mutations, the 30 end
metabolism was not affected (see Table 2); in these cases,
other levels are presumably responsible for pathology, as sug-
gested by the results of in vitro and in vivo studies by numerous
investigators [for example see (17,18) and references therein].
The defects were observed in tRNA synthesis and maturation,
including impaired termination of transcription, impaired
RNase P processing and absence of post-transcriptional mod-
ifications (especially of the anticodon triplet, hindering codon
reading). Post-aminoacylation functions of tRNA, including
interaction with EF-Tu, codon reading or polysome formation,
were sometimes affected. Decreased stability is the most com-
mon feature of mutant mitochondrial tRNAs associated with
pathogenesis.
Structural aspects
As discussed above, the mechanisms by which mutations in
tRNA affect the enzymatic activities of tRNA metabolism
remain largely unknown. Mutations may interfere directly
with recognition by the concerned enzyme, or change the
overall structure enough to perturb the recognition. Owing
to the intrinsic structural weakness of human mitochondrial
tRNAs, the effect of mutations on tRNA structure may be
amplified. Most of the pathology-associated mutations are
conservative nucleotide transitions (90). When found in
stems, canonical base pairs are often changed to weak G-U
(U-G) wobble pairs or to CA (AC) mismatches (see Figure 3).
In many cases, the effect on stem structure would be expected
to be mild, because G-U and CA can hydrogen bond with
strength comparable to the A-U pair (91). Their structural
effect could be magnified, however, since they are often
found in regions which are already thermodynamically
weak (18). Further illustrating this point, A4309G in the
T-stem of tRNAIle displays a weakened secondary structure
(46), and T3271C in the anticodon stem of tRNALeu(UUR) loses
its negative effect on aminoacylation when combined with a
stabilizing substitution in the D-stem (82).
EFFECTIVENESS AND CAVEATES CONCERNING
USE OF IN VITRO TRANSCRIPTS AS TOOLS
FOR SYSTEMATIC SCREENING
The results summarized here on the potential impact of mito-
chondrial tRNA mutations on 30 end metabolism were
obtained using in vitro transcribed substrate tRNAs or
tRNA precursors. The in vitro strategy of RNA preparation
is of particular interest for human mitochondrial tRNAs since
it allows the preparation of a large amount of any tRNA (either
wild-type or mutant). Furthermore, in vitro kinetic analysis
can lead to mechanistic insight. The structural flexibility of
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these tRNAs leads, in some cases, to the need to create
‘pseudo-wild-type’ molecules which have a single mutation
introduced to stabilize structure and allow correct folding.
Thoroughly documented in at least two cases [tRNALys and
tRNALeu(UUR)] to react in a manner comparable to that of the
corresponding natural tRNAs extracted from cells, we believe
they are relevant substitutes which allow useful analyses of
second-site (pathogenesis-associated) mutations.
The lack of post-transcriptional modifications can be a
drawback since such modifications can affect the structure
and function of tRNA (92). Post-transcriptional modifications
in classical tRNAs play either of two major roles, stabilizing
tRNA structure and/or providing a recognition element for
interacting partners such as aminoacyl-tRNA synthetases or
mRNA codons. Therefore, aminoacylation properties of
in vitro transcripts may be different from those of fully mod-
ified tRNAs in vivo. However, mutations introduced into the
‘pseudo-wild-type’ molecules are designed to stabilize the
tRNA structure, replacing the structural role of the naturally
occurring modifications to the extent that is feasible and
allowing for efficient aminoacylation.
The in vitro approach is also valid when testing 30 end
maturation activities such as tRNase Z activity, because this
enzyme processes primary transcripts which may not yet be
modified. Concerning CCA addition, this reaction can take
place before all modifications are introduced into the tRNA
(93). CCA-adding enzyme requires a properly folded tRNA
acceptor stem to synthesize the CCA triplet; this domain has
been shown to be correctly folded in the case of in vitro
transcripts which have been analyzed for CCA addition
[tRNAIle, tRNAGly and tRNALeu(UUR)]. Modified nucleotides
may thus be unnecessary for CCA addition and by inference,
for the preceding tRNase Z reaction.
Significance of small effects of mutations on
enzyme activities measured in vitro
Two major questions affect the interpretation of measured
kinetic values. (i) To what extent do in vitro effects reflect
the in vivo situation? (ii) Do small effects on reaction effi-
ciency contribute to the expression of disorders? The first
question is difficult to answer since in vitro assays take into
account neither possible competition events nor the cellular
environment, which the in vivo approach does. Moreover, one
approach measures kinetic parameters of an enzymatic reac-
tion leading to a value for efficiency, while the other measures
the steady-state level of reaction products (e.g. aminoacyl-
tRNA). These parameters cannot be compared directly, lead-
ing to apparent discrepancies between some of the in vitro and
in vivo results. A valuable approach would be to measure
reaction kinetics using in vitro wild-type and mutated tran-
scripts and corresponding native wild-type and mutated tRNAs
extracted from cybrid cell lines. In the case of tRNALys, results
were the same (20,79). In the case of tRNALeu(UUR), however,
results were significantly different (21). The native mutated
tRNALeu(UUR) (A3243G) showed a 25-fold loss in amino-
acylation efficiency when compared to the corresponding
wild-type tRNA, while the mutated in vitro transcript only
led to a 2.5- to 3-fold loss compared to the wild-type transcript.
The transcripts can thus underestimate the impact of mutations;
they can nonetheless usefully serve as indicators/detectors of
the effects of mutation on aminoacylation.
Concerning the magnitude of effects and their relevance to
pathology, Table 2 shows between 2.1- and 12.5-fold effects of
mutations on cleavage of the 30-trailer and at most a 5.5-fold
decrease in efficiency of CCA addition. On the other hand,
effects on aminoacylation properties of transcripts can be
much greater, ranging from a 2-fold to a several 1000-fold
decrease in efficiency. While several 1000-fold reductions in
aminoacylation would be expected to contribute strongly to
pathogenicity, even small reductions in individual maturation
steps can contribute to the onset of disease, amplified by the
cumulative effects of these impairments. Along these lines, the
A4269G mutation in tRNAIle displays a 2-fold decrease in
affinity for EF-Tu (94).
FUTURE PROSPECTS
Pathogenesis-associated tRNAs may contribute to mitochon-
drial disease due to individual effects or to accumulation of a
number of deficiencies in end maturation, including 30 end
cleavage by tRNase Z and CCA addition by tRNA nucleotidyl-
transferase, and in aminoacylation. Effects of the pathogenesis-
associated substitutions on these reactions, analyzed using in
vitro transcripts, doesnotpreclude otherevents, including 50 end
processing by RNase P, post-transcriptional modifications,
elongation factor binding, ribosome binding, etc.
One promising direction is the analysis of nuclear-encoded
enzymes involved in mitochondrial tRNA metabolism. In the
case of enzymes encoded by single genes which are targeted to
the mitochondria, cytoplasm and/or nucleus, it will be important
to establish the relative enzyme concentrations in the individual
compartments, which will greatly influence tRNA metabolism.
Virtually all pathogenesis-associated tRNA mutations can
be investigated using in vitro transcripts. It will thus be possible
to quantify and classify the effect(s) of individual mutations on
metabolism as it relates to pathogenicity and to accumulate
fundamental information concerning structure/function rela-
tions in human mitochondrial tRNAs. Although the in vitro
strategy is not universally applicable, it is a valuable approach
for unraveling many aspects of tRNA-based mitochondrial
pathology before undertaking more costly in vivo analyses.
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